Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

L.A. McKeown

November 25, 2024

News Daily News

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

L.A. McKeown

February 02, 2024

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Daily News

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Michael O'Riordan

January 17, 2023

News Daily News

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

L.A. McKeown

August 23, 2022

News Daily News

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

Shelley Wood

September 20, 2021

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Shelley Wood

June 01, 2020

News Conference News STS 2020

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

Yael L. Maxwell

January 29, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

Todd Neale

August 19, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

Vici Venous Stent Receives FDA Approval for Iliofemoral Obstructive Disease

L.A. McKeown

May 06, 2019

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Daily News

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Shelley Wood

April 24, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

Todd Neale

May 04, 2018

Advertisement

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Acoramidis Approved in Europe for ATTR Cardiomyopathy

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

FDA Approves Colchicine for Decreasing CV Events

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

Funding the Future: How Industry Support for CV Trials Could Evolve

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

FDA Expands TAVR Indication to Low-Risk Patients

Vici Venous Stent Receives FDA Approval for Iliofemoral Obstructive Disease

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

FDA Approves Lotus Edge, Ushering Third Device Into US Market

TCTMD’s Top 10 Most Popular Stories for January 2019

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content